CYTOGEN BLAMES LOWER REVENUES ON CONTRACT REVENUECytogen Corp. (NASDAQ:CYTO) of Princeton, N.J., Chief FinancialOfficer Martin D. Cleary said: "In the first quarter of 1990,Cytogen recorded the majority of the Sterling Drug researchservices annual commitment. Although the annual commitmentto funding for 1991 has remained unchanged, only 4 percentwas recorded in this year's first quarter. Until we have productsales, we must continue to endure these quarter-to-quarterfluctuations in contract revenue."

First quarter ended March 30

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $1,149 1,689 -32Operating expenses 5,626 5,262 -7Net income (loss) (4,477) (3,573) -25Net income per share (loss) (.31) (.32) +3Outstanding shares 15,859 12,368 -28

MGI PHARMA INCREASES REVENUES, DEEPENS LOSS

MGI Pharma Inc. (NASDAQ:MOGN) of Minneapolis said revenuesfor the quarter included a one-time gain for $436,782 on thesale of the company's remaining interest in MogenInternational, N.V., and an increase in sales of Didronel I.V.Infusion. Chief Executive Officer Dr. Kenneth Tempero said: "Ourclinical trials remain on course and our commercial operationscontinue to increase product revenues and expand thecompany's reputation in the oncology marketplace.Additionally, we continue to manage our financial resourceseffectively. We ended the quarter with nearly $26 million incash, cash equivalents and short-term investments."

First quarter ended March 31

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $2,260 1,429 +58Net income (loss) (1,572) (1,458) -8Net income per share (loss) (.20) (.18) -11Outstanding shares 8,252 8,198 neg.

GREENWICH ATTRIBUTES REVENUES HIKE TO SYNTEX DEAL

Greenwich Pharmaceuticals Inc. (NASDAQ:GRPI) said "the sharpincrease in revenues was due to substantially higher revenuesfrom Syntex Corp. pursuant to the February 1989 developmentand license agreement in connection with the clinicaldevelopment of Therafectin (amiprilose HC10) and revenuesfrom Kissei Pharmaceuticals Co. Ltd. for pre-clinicaldevelopment of 80126, one of the company's new compounds,which were received in connection with an exclusive optionand development agreement formed in February 1991."

First quarter ended March 31

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $1,451 125 +1,061Operating expenses 4,797 2,540 +89Net income (loss) (3,346) (2,415) -39Net income per share (loss) (.14) (.11) -27Outstanding shares 24,047 21,970 +9

IAF BIOCHEM REPORTS LOSS FOR YEAR

IAF BioChem International Inc. (NASDAQ:BCHXF) ofLaval,Quebec,said the company's share in the losses of NorthAmerican Vaccine Inc. resulted in a net loss for the year.

Fiscal Year Ended Jan. 31.

(Figures in thousands of U.S. dollars except per-share data.)

1990 1989 Percent change

Revenues $14,314 5,397 +165Operating expenses 5,494 2,882 +91Net income (loss) (805) 196 -511Net income per share (loss) (.06) .02 -400

CYTRX REPORTS PROFIT

CytRx Corp. (NASDAQ:CYTR) of Norcross, Ga., President and ChiefExecutive Officer Jack J. Luchese said: "The first-quarter resultsinclude the $500,000 option exercise fee by BurroughsWellcome for rights to RheothRx in Japan. First-quarterrevenues also include sales of Hunter's TiterMax, animmunoadjuvant which was launched in December 1990. Theprofit turnaround vs. the prior year was primarily due toRheothRx licensing revenues and improved control of operatingcosts."

First quarter ended March 31

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $1,068 15 +7020Net income (loss) 562 (623) +190Net income per share (loss) .03 (.03) +200

INVITRON REPORTS LOSS FOR QUARTER, YEAR

The board of directors of Invitron Corp. (NASDAQ:INVN) of St.Louis on Jan 31 adopted a plan of complete liquidation anddissolution and recommended to the company's shareholdersthat it be approved.

Fourth quarter ended Dec. 31, 1990

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $1,934 1,633 +18Operating expenses 3,162 8,046 -61Net income (loss) (1,171) (5,987) -80Net income per share (loss) (.08) (.39) -79Outstanding shares 15,576 15,427 neg.

Fiscal Year ended Dec. 31, 1990

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $5,189 11,458 -55Operating expenses 20,995 30,149 -30Net income (loss) (14,456) (16,447) +12Net income per share (loss) (.93) (1.07) +13Outstanding shares 15,568 15,365 +1

REPLIGEN'S REVENUES DOWN FOR QUARTER, YEAR

Repligen Corp. (NASDAQ:RGEN) of Cambridge, Mass., Presidentand Chief Executive Officer Sandford D. Smith said: "Losses forthe year, which were in line with expectations, were due, inpart, to product scale-up in preparation for clinical evaluationand increased spending for research and development. Thecompany also has incurred expenses related to its launch of anew program to develop anti-inflammation therapeutics."

Fourth quarter ended March 31

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $2,591 3,045 -15Net income (loss) (1,496) (1,483) neg.Net income per share (loss) (.16) (.18) +11Outstanding shares 9,266 8,395 +10

Fiscal Year Ended March 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $10,249 12,790 -20Net income (loss) (5,714) (2,399) -138Net income per share (loss) (.63) (.31) -103Outstanding shares 9,048 7,669 +18

(c) 1997 American Health Consultants. All rights reserved.